Oral therapies for the treatment of pulmonary arterial hypertension
Ambrisentan is less costly than other available ERAs, including bosentan and sitaxentan, but is more costly than sildenafil. In PAH patients in whom an ERA is the preferred agent, ambrisentan may be the drug of choice because of its economic advantages and improved safety profile. </AbstractSection> Copyright Adis Data Information BV 2009
Year of publication: |
2009
|
---|---|
Authors: | Dranitsaris, George ; Mehta, Sanjay |
Published in: |
Applied Health Economics and Health Policy. - Springer, ISSN 1175-5652. - Vol. 7.2009, 1, p. 43-59
|
Publisher: |
Springer |
Saved in:
Online Resource
Saved in favorites
Similar items by person
-
Dranitsaris, George, (2010)
-
Dranitsaris, George, (2009)
-
Benchmarks for shop scheduling problems
Demirkol, Ebru, (2006)
- More ...